INDRAPRASTHA MEDICAL CORP vs TORRENT PHARMACEUTICALS L

A side-by-side comparison of INDRAPRASTHA MEDICAL CORP (INDRAMEDCO) and TORRENT PHARMACEUTICALS L (TORNTPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, TORRENT PHARMACEUTICALS L leads INDRAMEDCO vs TORNTPHARM on 8 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation31
  • Profitability13
  • Growth11
  • Size & financial health13
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

INDRAMEDCO takes 3/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

17.62
P/E ratio
78.26
4.57
P/B ratio
18.67
1.08%
Dividend yield
0.76%
₹20.03
EPS
₹63.92

Profitability

TORNTPHARM takes 3/4

How efficiently each company turns capital and sales into profit. Higher is better.

24.83%
Return on equity
27.40%
36.00%
Return on capital
15.00%
18.00%
EBITDA margin
33.00%
12.39%
Net margin
15.29%

Growth

Even

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.49%
Revenue CAGR (3Y)
13.27%
28.77%
Profit CAGR (3Y)
19.75%

Size & financial health

TORNTPHARM takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹3,239 Cr
Market cap
₹1.90L Cr
₹1,483 Cr
Revenue
₹13,980 Cr
₹184 Cr
Net profit
₹2,138 Cr
0.05
Debt / equity
1.69
INDRAPRASTHA MEDICAL CORP
  • + ["Company is almost debt free.", "Company has delivered good profit growth of 132% CAGR over last 5 years", "Company has a good return on equity (ROE) track record: 3 Years ROE 28.8%", "Company has been maintaining a healthy dividend payout of 26.3%"]
TORRENT PHARMACEUTICALS L
  • + ["Company is expected to give good quarter", "Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 57.8%"]
  • ["Stock is trading at 20.4 times its book value", "Promoter holding has decreased over last quarter: -7.53%", "The company has delivered a poor sales growth of 11.8% over past five years.", "Company might be capitalizing the interest cost"]
INDRAPRASTHA MEDICAL CORP full analysis TORRENT PHARMACEUTICALS L full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.